Heart Failure, Left Sided Clinical Trial
Official title:
Evaluation of Professional Practices on the Management of Cardiogenic Pulmonary Edema (RENAU-OAP)
The prevalence of heart failure is estimated to 2.3 percent of the adult population and
strongly increases with age, according to french disability-health surveys. In France, more
than 32,000 annual deaths are attributable to heart failure and the five-year survival rate
is similar to those found in many cancers. A better therapeutic management (angiotensin
converting enzyme inhibitor and beta-blockers) helped reduce mortality after an episode of
heart failure requiring hospitalization, but, nevertheless it remains high.
The severity of cardiogenic pulmonary edema depends on several factors such as etiology,
hemodynamic status, effect on hematosis, and fatigue.
It is important to note that cardiogenic pulmonary edema initial management is decisive. In
addition, early and adapted management of cardiogenic pulmonary edema is associated with a
shorter hospital stay and reduced hospital mortality.
The Coronary Emergency Network (RESURCOR) within the Northern French Alps Emergency Network
(RENAU) is an emergency care system structured in the departments of Isère, Savoie and Haute
Savoie. Its main goal is to help improve emergency management by using regional good practice
guidelines (www.renau.org). In this context, projects aiming to evaluate professional
practices are developed regularly. Since emergency management of cardiogenic pulmonary edema
has not been evaluated, the Northern French Alps Emergency Network offers an approach to
improve professional practices by defining and disseminating guidelines on cardiogenic
pulmonary edema management which will then be assessed.
The prevalence of heart failure is estimated to 2.3 percent of the adult population and
strongly increases with age, according to disability-health surveys in France. In recent
years, effective treatments (revascularization in percutaneous coronary intervention,
circulatory assistance) helped reduce mortality in post-myocardial infarction, which combined
with the increase of life expectancy has led to an increase number of patients with chronic
heart failure. More than 32,000 annual deaths are attributable to heart failure and the
five-year survival rate is similar to those found in cancers of the breast, bladder, colon,
ovarian, and prostate. A better therapeutic management (angiotensin converting enzyme
inhibitor and beta-blockers) helped reduce mortality after an episode of heart failure
requiring hospitalization, but, nevertheless it remains high.
Main clinical manifestations are those of left heart failure, such as cardiogenic pulmonary
edema which is a medical emergency. Treatment must take into account pathophysiological
aspects of heart failure, etiologies of cardiogenic pulmonary edema and any potential factors
or triggers apart from general measures. Two consensus statements and an international
recommendation help define therapeutic strategies in this particular situation.
Signs suggestive of cardiogenic pulmonary edema include orthopnea, bilateral crackles or
wheezing (patients over 70 years without known asthma), edema of the lower limbs, and gallop
sound on heart auscultation. The evolution of these signs makes it particularly possible to
manage the response to the treatment. The severity of cardiogenic pulmonary edema depends on
several factors such as etiology (ECG analysis and chest pain assessment for acute coronary
syndrome), hemodynamic status (blood pressure, heart rate), effect on hematosis (cyanosis,
oxygen saturation), and fatigue (low respiratory rate with persistent cardiogenic pulmonary
edema signs). The respiratory rate represents a simple clinical feature that can be used to
quantify dyspnea (sign of severity if greater than 30 per minute in adults) and then follow
its evolution (improvement, exhaustion). Disorders of consciousness can testify to the
severity of the hemodynamic state and/or exhaustion.
Cardiogenic pulmonary edema management without shock implies urgent administration of
vasodilators (trinitrin) and intravenous loop diuretics in presence of congestion signs along
with the establishment of a system of care adapted to severity (Emergency Mobile Services or
ambulance, hospitalization in Intensive Care Unit, intensive cardiology unit, cardiology or
medicine department, or emergency passage). The subsequent therapeutic management will
especially depend on initial treatment by the primary care physician, so it is preferable to
record doses and hours of medications. Non-hospitalization must remain exceptional for
non-severe decompensation with rapidly favorable evolution.
The French Observatory of Acute Heart Failure (OFICA) including nearly 1,800 patients
specified epidemiological and therapeutic data of patients hospitalized for cardiogenic
pulmonary edema in 2009. However, this study did not describe the initial management of the
Mobile Emergency and Resuscitation Service and emergency services of hospitals. It is
important to note that cardiogenic pulmonary edema initial management is decisive. In
addition, early and adapted management of cardiogenic pulmonary edema is associated with a
shorter hospital stay and reduced hospital mortality.
The Coronary Emergency Network (RESURCOR) within the Northern French Alps Emergency Network
(RENAU) is an emergency care system structured in the departments of Isère, Savoie and
Haute-Savoie. Its main goal is to help improve emergency management by using regional good
practice guidelines (www.renau.org). In this context, projects aiming to evaluate
professional practices are developed regularly. Since emergency management of cardiogenic
pulmonary edema has not been evaluated, the Northern French Alps Emergency Network offers an
approach to improve professional practices by defining and disseminating a guideline on
cardiogenic pulmonary edema management which will then be assessed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05230745 -
ContraBandâ„¢: FIH Safety & Feasibility Study (RM-20-01)
|
N/A | |
Terminated |
NCT03774615 -
ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices
|
Phase 4 | |
Active, not recruiting |
NCT05350969 -
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
|
Phase 2 | |
Completed |
NCT04397302 -
Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction
|